Table 1.
Clinical features of malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) and non-malignancy–associated hemophagocytic lymphohistiocytosis (N-M-HLH)
| M-HLH (n = 22) | N-M-HLH (n = 69) | Statistic value | p-value | Q value | |
|---|---|---|---|---|---|
| Age [year; median (min, max)] | 3.60(0.25,13.00) | 1.20(0.20,13.00) | −2.216† | 0.027b | 0.135 |
| Sex | |||||
| Male | 13.00(59.10%) | 39.00(56.50%) | 1.111* | 0.045a | 0.113 |
| Female | 9.00(40.90%) | 30.00(43.50%) | |||
| Splenomegaly | |||||
| No | 3.00(13.60%) | 22.00(31.90%) | 2.965* | 0.095a | 0.211 |
| Yes | 19.00(86.40%) | 47.00(68.10%) | |||
| Neutrophils [109/L; median (min, max)] | 1.04(0.05,8.00) | 1.10 (0.05,10.50) | −0.496† | 0.620b | 0.775 |
| Hemoglobin [g/dL; median (min, max)] | 69.50(54.00,115.00) | 85.00 (31.00,131.00) | −2.879† | 0.004b | 0.027 |
| Platelets [109/L; median (min, max)] | 43.50(2.00,293.00) | 62.00 (7.00,418.00) | −2.077† | 0.038b | 0.109 |
| TG [mg/dL; median (min, max)] () | 3.13(0.81,7.55) | 3.42 (0.05,13.56) | −0.385† | 0.700b | 0.778 |
| Fibrinogen [mg/dL median (min, max)] | 1.24(0.58,5.00) | 1.20 (0.27,4.56) | −0.959† | 0.337b | 0.518 |
| Ferritin [mg/dL; median (min, max)] | 1148.50(354.00,21,173.00) | 3562.00 (132.00,27,810.00) | −0.742† | 0.458b | 0.654 |
| LDH [IU/L; median (min, max)] | 1002.50(227.00,17,958.00) | 936.00 (156.00,5311.00) | −0.649† | 0.516b | 0.688 |
| DIC | |||||
| No | 18.00(81.80%) | 44.00(63.80%) | 0.391* | 0.114a | 0.228 |
| Yes | 4.00(18.20%) | 25.00(36.20%) | |||
| Jaundice | |||||
| No | 14.00(63.60%) | 40.00(58.00%) | 0.788* | 0.638a | 0.751 |
| Yes | 8.00(36.40%) | 29.00(42.00%) | |||
| Hemophagocytosis | |||||
| Yes | 16.00(72.70%) | 37.00(53.60%) | 2.306* | 0.114a | 0.207 |
| No | 6.00(27.30%) | 32.00(46.40%) | |||
| EBV | |||||
| Positive (EBV DNA > 1.44 × 103/copies) | 8.00(36.30%) | 21.00(30.40%) | 1.306* | 0.037a | 0.123 |
| Negative (EBV DNA < 1.44 × 103/copies) | 14.00(63.70%) | 48.00(69.60%) | |||
| ALT [g/L; median (min, max)] | 77.50(17.00,403.00) | 210.00(3.00,5679.00) | −3.110† | 0.002b | 0.02 |
| AST [g/L; median (min, max)] | 87.50(19.00,320.00) | 210.00(12.00,7654.00) | −3.407† | 0.001b | 0.02 |
| Albumin [g/L; median (min, max)] | 30.00(18.80,37.60) | 29.00 (17.91,40.30) | −0.269† | 0.788b | 0.829 |
| Cholecystitis | |||||
| Yes | 1.00(4.5%) | 10.00(14.5%) | 0.281* | 0.213a | 0.355 |
| No | 21.00(95.5%) | 59.00(85.5%) | |||
| Pneumonia | |||||
| Yes | 10.00(45.50%) | 32.00(46.40%) | 0.964* | 0.940a | 0.940 |
| No | 12.00(54.50%) | 37.00(53.60%) | |||
| Pleural effusion | |||||
| Yes | 3.00(13.60%) | 26.00(37.70%) | 0.261* | 0.035a | 0.140 |
| No | 19.00(86.40%) | 43.00(62.30%) | |||
TG Triglyceride, LDH Lactate dehydrogenase, DIC Disseminated intravascular coagulation, HLH Hemophagocytic lymphohistiocytosis
Q-value: P value after multiple group corrections
ap-value for χ2 test; *: Odds Ratio for Chi-square test
bp-value for Mann–Whitney U test; †: Z value for Mann–Whitney U test